Zoledronate blocks geranylgeranylation not farnesylation to suppress human osteosarcoma U2OS cells metastasis by EMT via Rho A activation and FAK-inhibited JNK and p38 pathways.

Cheng, Hsin-Lin

Zoledronate blocks geranylgeranylation not farnesylation to suppress human osteosarcoma U2OS cells metastasis by EMT via Rho A activation and FAK-inhibited JNK and p38 pathways. [electronic resource] - Oncotarget Mar 2016 - 9742-58 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1949-2553

10.18632/oncotarget.7138 doi


Biological Transport--drug effects
Bone Density Conservation Agents--pharmacology
Bone Neoplasms--drug therapy
Cadherins--metabolism
Cell Line, Tumor
Cell Movement--drug effects
Cell Survival--drug effects
Diphosphonates--pharmacology
Diterpenes--pharmacology
Epithelial-Mesenchymal Transition--drug effects
Farnesol--pharmacology
Focal Adhesion Kinase 1--metabolism
Focal Adhesion Protein-Tyrosine Kinases--metabolism
Humans
Imidazoles--pharmacology
JNK Mitogen-Activated Protein Kinases--metabolism
MAP Kinase Signaling System--drug effects
Neoplasm Invasiveness--pathology
Nuclear Proteins--metabolism
Osteoporosis--chemically induced
Osteosarcoma--drug therapy
Phosphorylation--drug effects
Prenylation--drug effects
Proto-Oncogene Proteins pp60(c-src)--metabolism
Snail Family Transcription Factors--metabolism
Twist-Related Protein 1--metabolism
Zoledronic Acid
cdc42 GTP-Binding Protein--metabolism
p38 Mitogen-Activated Protein Kinases--metabolism
rho-Associated Kinases--metabolism